Ranibizumab
As of the edition of 20 October 2026, Ranibizumab is an antibody: marketed, first approved in 2006 (US); acts on VEGFA; US protection ended in 2018.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Antibody
- Brand name
- Lucentis
- First approved
- 30 June 2006 (US)
- Approvals on record
- 16 in 5 regions
- Holder of the most recent approval
- Roche; 6 holders in all
- Registered trials
- 384, 44 stopped early
- Disease areas
- Eye; Heart and blood vessels; Hormones; Nervous system; Inherited and neonatal; Nutrition and metabolism
US protection
US protection ended in 2018.
US protection ended in 2018, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Roche. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 65 | 43 | 2 | 4 |
| Phase 1 | 42 | 33 | 0 | 6 |
| Phase 2 | 107 | 85 | 1 | 13 |
| Phase 3 | 90 | 60 | 6 | 12 |
| Phase 4 | 80 | 51 | 1 | 9 |
| All trials | 384 |